What the research found

Endometriosis and adenomyosis are chronic conditions where tissue similar to the uterine lining grows in abnormal locations, most commonly outside the uterus. These conditions remain frequently underdiagnosed despite affecting millions of women globally. Modern imaging—specifically MRI and specialized ultrasound—now offers non-surgical diagnostic pathways, moving beyond the historical reliance on laparoscopy.

The prevalence of endometriosis appears linked to a combination of genetic predisposition and modern reproductive patterns. Women with a first-degree relative who has endometriosis face substantially elevated risk. A key mechanistic factor is retrograde menstruation—where menstrual tissue flows backward through the fallopian tubes into the pelvis—which occurs in most women but appears more frequent in modern life due to extended reproductive years and more ovulatory cycles. Historical reproductive patterns (more pregnancies, less menstruation) created fewer opportunities for this backward flow. Current treatment options include hormonal suppression of ovulation and menstruation, or surgical intervention, with the choice depending on fertility intentions and disease severity.

Why it matters for you

If you're a woman tracking hormonal biomarkers or considering fertility preservation, endometriosis and adenomyosis merit attention because they directly affect both ovulation quality and conception likelihood—roughly 40% of women with endometriosis experience infertility. The genetic component means family history should inform your health screening priorities.

The connection to menstrual frequency has practical implications for your protocol decisions. Hormonal contraceptives, progesterone-based approaches, and other ovulation-suppressive strategies aren't just contraception in this context—they're therapeutic tools that reduce the cumulative burden of retrograde menstruation. If you're tracking cycle metrics, energy levels, or inflammatory markers, these interventions would show measurable effects. For those prioritizing fertility, understanding the diagnostic distinction between endometriosis and adenomyosis becomes crucial, since treatment pathways differ and surgery may be appropriate in some cases but not others.

Age-related egg quality decline (accelerating chromosomal abnormalities after 35) compounds these conditions' impact on fertility timelines, making early diagnosis particularly valuable for reproductive planning.

Caveats

  • This is an expert overview, not original research—no new studies or effect sizes are presented
  • The historical comparison regarding menstrual frequency is observational and retrospective
  • Specific prevalence rates, treatment efficacy data, and fertility outcome statistics are not detailed in the source
  • No discussion of racial or demographic variation in endometriosis diagnosis or outcomes
  • The interplay between immune dysregulation and disease is mentioned but not explained in mechanistic depth